3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
33
Phase 3
18
Phase 1
18
Phase 1/2
8
Phase EARLY_PHASE1
5
Phase 4
2
Phase NA
1
Phase 2/3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Genitourinary
1
Conditions
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
BRCA or HRR+ Mutated Ovarian Cancer Patients
1
Interventions
niraparib
4
olaparib
2
apatinib
2
Sevoflurane
2
Saline Solution
2
Propofol
2
Carboplatin
2
Bevacizumab
2
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
palbociclib
1
liposomal doxorubicin
1
lenvatinib
1
gadofosveset trisodium
1
fosaprepitant
1
ferrous fumarate
1
Tranexamic Acid
1
Trabectedin
1
Sunitinib
1
Sodium Chloride
1
Pharmacokinetics
1
Patient-Specific Modeling
1
Pafolacianine
1
Paclitaxel
1
LY 353381
1
Injections
1
Indocyanine Green
1
Folic Acid
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Ovarian Neoplasms
×
olaparib
×
Clear all
NCT04330040
2025-03-10
SOLI
AstraZeneca
Phase 4
Completed
202 enrolled
15 charts
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled